The 'Godmother of AI' Helped Spark Nvidia's AI Boom. Now She's Joining AMD. AMD is bringing in Fei-Fei Li, whose work helped launch Nvidia's AI boom, and her research could help AMD close the gap. Barchart · Sep 30
Dear Palantir Stock Fans, Here’s What Maven’s Billion-Dollar ARR Means for PLTR PLTR stock continues to rise amid strong quarterly results and bullish commentary about Palantir's Maven smart system. Barchart · Aug 31
This Analyst Just Upgraded Moderna as MRNA Stock Skyrockets on Cancer Vaccine Results Moderna stock rips higher on a major cancer breakthrough. The announcement led William Blair to upgrade MRNA shares to "Outperform." Barchart · Aug 19
SpaceX vs Blue Origin: Why Musk's Record IPO Gave Bezos a $130B Valuation Rather Than Denting It SpaceX's record-breaking IPO influenced Blue Origin's valuation and the subsequent market shifts. Understand the implications for investors and the space industry. International Business Times UK · Jul 31
Microsoft’s stock has biggest one-day gain since 2008, adding $480 billion in market value as cloud business booms Azure crossed $100 billion in revenue for the first time, and a new disclosure about OpenAI offered some respite. Fortune · Jul 30
If You Lack Conviction in This Market, Here’s 1 Stock William Blair Thinks Deserves Your Attention William Blair just added ORCL stock to its conviction list, with Oracle expected to be a major AI beneficiary. Barchart · Jul 3
Black Rock Coffee Bar Targets 1,000 Stores as Loyalty Fuels Growth Plan Black Rock Coffee Bar (NASDAQ:BRCB) executives outlined the company’s growth strategy, store economics and competitive positioning during a William Blair consumer event, emphasizing plans to sustain rapid unit expansion while leaning on customer loyalty, store-level execution and a differentiated ca MarketBeat · Jun 6
BlackLine Says AI Agents, Platform Pricing Can Reignite Revenue Growth BlackLine (NASDAQ:BL) executives said the company is leaning on platform pricing, artificial intelligence and deeper enterprise adoption as it works to reaccelerate revenue growth, according to remarks at a William Blair conference session. Chair and CEO Owen Ryan described BlackLine as a “mission- MarketBeat · Jun 6
AeroVironment Sees Drone Demand Taking Off as Switchblade, Counter-Drone Capacity Expands AeroVironment (NASDAQ:AVAV) executives told investors at William Blair’s 46th Annual Growth Stock Conference that the company sees expanding opportunities across drones, loitering munitions and counter-drone systems, while also emphasizing ongoing capacity investments tied to programs such as Switch MarketBeat · Jun 6
argenx Touts VYVGART Growth, 50,000-Patient Goal at William Blair Conference argenx (NASDAQ:ARGX) Chief Financial Officer Karl Gubitz told investors at the 46th Annual William Blair Growth Stock Conference that the biotechnology company remains focused on revenue growth, profitability and execution as it expands the VYVGART franchise and advances additional pipeline assets. MarketBeat · Jun 5
Align Technology Pitches AI-Powered Digital Dentistry Platform Beyond Invisalign Align Technology (NASDAQ:ALGN) executives used a William Blair investor presentation to emphasize the company’s broader digital dentistry platform, positioning Invisalign as part of a workflow that spans consumer engagement, scanning, treatment planning, monitoring and retention. President and CEO MarketBeat · Jun 3
Appian CFO Says AI Workflows, Government Demand Are Driving Big-Customer Growth Appian (NASDAQ:APPN) Chief Financial Officer Serge Tanjga said the company is seeing stronger traction with large enterprise and government customers as it positions its low-code automation platform around regulated, mission-critical workflows and embedded artificial intelligence. Speaking at Willi MarketBeat · Jun 2
Alkami Technology Touts $500M ARR, AI Upside and Bank Demand at Fintech Event Alkami Technology (NASDAQ:ALKT) executives outlined the company’s growth strategy, financial outlook and market positioning during a William Blair fintech and payments event, emphasizing demand from regional banks and credit unions seeking digital capabilities comparable to large banks and fintechs. MarketBeat · Jun 2
AAON Sees HVAC Recovery, $1B Data Center Opportunity Despite Margin Pressure AAON (NASDAQ:AAON) executives outlined expectations for continued growth in both light commercial HVAC and data center markets during a William Blair presentation, while also addressing recent production challenges, margin pressure and ongoing efforts to scale the company’s operations. CEO Matt Tob MarketBeat · Jun 2
Barchart · May 6 Ignore the Amazon Trucking Noise and Buy UPS Stock for Its High Yield Near 7% While Amazon’s logistics push is weighing on UPS stock, investors may want to consider the company’s shareholder-friendly approach before writing it off.
Barchart · Mar 13 Is Carvana Stock a Buy on New Stock Split Announcement? Carvana stock inched up as the company announces 5-for-1 stock split. William Blair continues to recommend buying CVNA shares.
Barchart · Feb 2 Here’s What Options Traders Expect from Palantir Stock After Earnings Palantir stock has slipped below $150 ahead of its earnings release on Feb. 2. But a William Blair analyst says the trajectory will reverse after the quarterly report later today.
Benzinga · Dec 3, 2025 Analyst Says Viridian's New Thyroid Eye Drug Could Outperform Amgen's Tepezza William Blair initiated coverage on Viridian Therapeutics Inc. (NASDAQ:VRDN) on Wednesday.
Benzinga · Oct 23, 2025 Moderna Stops CMV Program As Vaccine Falls Short In Preventing Infection Moderna, Inc. (NASDAQ:MRNA) revealed topline results on Wednesday from a Phase 3 trial evaluating the efficacy of mRNA-1647, the company’s investigational cytomegalovirus (CMV) vaccine. CMV is a herpes virus. Those who are pregnant or have compromised immune systems are most at risk from CMV.
Benzinga · Oct 22, 2025 Thermo Fisher's Upbeat Earnings Suggest Worst Is Over For Scientific Tools Sector, Analyst Says Thermo Fisher Scientific Inc. (NYSE:TMO) on Wednesday reported third-quarter 2025 adjusted earnings of $5.79 per share, beating the street view of $5.49.
Benzinga · Oct 17, 2025 Kezar Launches Strategic Review As FDA Roadblock Derails Liver Drug Plans Kezar Life Sciences, Inc. (NASDAQ:KZR) announced regulatory updates and began exploring strategic alternatives.
Benzinga · Oct 16, 2025 Analyst Sees Noise In Q3 P&L, Affirms Abbott's Medtech Strength Abbott Laboratories (NYSE:ABT) reported muted sales in the third quarter on Wednesday and narrowed its fiscal 2025 guidance.
Benzinga · Oct 16, 2025 Small-Cap Biotech Climb Bio's Lead Drug Candidate Has Larger Long-Term Opportunity William Blair initiated coverage for Climb Bio (NASDAQ:CLYM), citing the potential of the company’s budoprutug, under development for autoimmune indications, including:
Benzinga · Sep 29, 2025 Genmab Makes $8 Billion Bet On Merus With Potential Cancer Breakthrough Genmab A/S (NASDAQ: GMAB) on Monday agreed to acquire Merus N.V. (NASDAQ: MRUS) with its late-stage asset petosemtamab, which is in Phase 3 development, for $97 per share in an all-cash transaction representing a transaction value of approximately $8 billion.
Benzinga · Sep 8, 2025 Dianthus Scores Early Success, Analyst Boosts Confidence In Broader Drug Pipeline Dianthus Therapeutics Inc. (NASDAQ:DNTH) released topline data from the Phase 2 MaGic trial evaluating the safety and efficacy of claseprubart (DNTH103) in adults with acetylcholine receptor antibody-positive (AChR+) generalized myasthenia gravis (gMG).